If You Invested in Nervgen Pharma Corp (NGENF)

NervGen Pharma Corp. (TSXV: NGEN, NASDAQ: NGEN, OTCQB: NGENF) is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. According to the company, its mission is to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease, with the goal of transforming the lives of individuals living with SCI.

The company’s lead therapeutic candidate is NVG-291, a subcutaneously administered neuroreparative peptide. NervGen holds exclusive worldwide rights to NVG-291, which is based on technology licensed from Case Western Reserve University. Academic studies of the rodent variant, NVG-291-R, in animal models of spinal cord injury have demonstrated preclinical efficacy and implicated multiple molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. These mechanisms include promotion of neuronal sprouting or plasticity, remyelination, and promotion of a non-inflammatory phenotype in microglial cells.

NVG-291 is being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with spinal cord injury. In the chronic cohort (individuals 1 to 10 years post-injury), NervGen has reported topline and expanded data showing that NVG-291 treatment was associated with durable improvements in function, independence, and quality of life compared to placebo. Reported findings include improvements in upper and lower body function, hand function, bladder control, and muscle spasticity, supported by neurophysiological evidence such as statistically significant reductions in hyperactive reticulospinal signaling and increases in corticospinal signaling.

The CONNECT SCI Study is a placebo-controlled trial in chronic SCI with daily subcutaneous NVG-291 or placebo for 12 weeks, followed by observation to assess durability of response. Participants have also undergone blinded, institutional review board–approved qualitative exit interviews, which, according to NervGen, highlight real-world functional gains and sustained improvements in daily independence and key quality of life domains. Enrollment of individuals with subacute SCI (20–90 days post-injury) in the Phase 1b/2a CONNECT SCI Study is ongoing.

NervGen reports that NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gains in chronic cervical incomplete SCI. In the chronic cohort, NVG-291 met a primary endpoint related to electrophysiological connectivity and demonstrated strong trends or improvements across functional assessments, including measures such as the Graded Redefined Assessment of Strength, Sensation & Prehension (GRASSP). The company has also described NVG-291 as a first- and potential best-in-class therapeutic peptide targeting nervous system repair.

Regulatory interactions are a key part of NervGen’s development strategy. The company has completed a U.S. Food and Drug Administration (FDA) Type C meeting to discuss clinical development plans and the potential for accelerated approval. NervGen states that the FDA confirmed that multiple regulatory pathways are available to support approval of NVG-291 for SCI, given the significant unmet medical need and the lack of any approved pharmacologic treatments. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of spinal cord injury. NervGen has indicated plans for an FDA End-of-Phase 2 meeting to align on the development and registration pathway for NVG-291 and has referenced preparation for a Phase 3 clinical trial in chronic SCI.

Beyond spinal cord injury, NervGen highlights preclinical data suggesting broader therapeutic potential for NVG-291. In U.S. Department of Defense–sponsored studies, NVG-291-R demonstrated statistically significant functional recovery in models of blast-induced sensorineural hearing loss and peripheral nerve injury. In these models, daily subcutaneous NVG-291-R treatment led to statistically significant improvements in hearing thresholds across frequencies and improved neuromuscular function and axonal regrowth, with associated increases in compound muscle action potentials, specific tetanic force, and axon number and density distal to the injury site. These results reinforce the company’s view that NVG-291 may have broad application across multiple neurological conditions involving nervous system damage.

NervGen also reports that it has filed a patent application related to NVG-291’s ability to reduce hyperactive reticulospinal signaling and muscle spasticity, with the aim of strengthening its intellectual property position and supporting the candidate’s potential across neurotraumatic indications. The company describes its overall approach as creating pharmacologic therapies that promote nervous system repair and neuroreparative mechanisms in neurotrauma and neurologic disease.

In addition to NVG-291, NervGen has disclosed a next-generation pipeline candidate, NVG-300. The company has initiated preclinical test-of-concept evaluation of NVG-300 in models of ischemic stroke and spinal cord injury, positioning it as a potential follow-on asset within its neurorepair-focused pipeline.

From a corporate and capital markets perspective, NervGen is headquartered in Vancouver, British Columbia, and has been listed on the TSX Venture Exchange under the symbol NGEN and on the OTCQB under NGENF. The company has also announced that its common shares have been approved for listing on Nasdaq and that they will trade on Nasdaq under the symbol NGEN. NervGen has used mechanisms such as an at-the-market equity program, private placements, and warrant issuances to fund its clinical and preclinical programs and corporate activities. The company has stated that a Nasdaq listing is expected to enhance visibility in the marketplace, improve liquidity, broaden and diversify its shareholder base, and support its long-term growth strategy as it advances NVG-291.

NervGen’s communications emphasize its collaboration with the spinal cord injury community, clinical experts, and patient advocacy organizations, as well as its engagement with regulators. The company frames its work on NVG-291 and NVG-291-R as part of an effort to establish a new treatment paradigm in spinal cord injury and related neurologic conditions, where pharmacologic therapy could restore function and increase independence for individuals living with the long-term consequences of neurotrauma.

Business focus and development strategy

NervGen’s core business focus is on discovering, developing, and clinically validating neuroreparative therapeutics that enable nervous system repair. The company is in the clinical stage, with its lead asset NVG-291 in human trials and additional preclinical work on NVG-291-R and NVG-300. Its development strategy, as described in its public communications, includes:

• Conducting the Phase 1b/2a CONNECT SCI Study in chronic and subacute spinal cord injury to evaluate safety, electrophysiological endpoints, and functional outcomes.
• Performing comprehensive analyses of NVG-291’s efficacy profile, including quantitative measures and qualitative exit interviews, to inform regulatory discussions.
• Engaging with the FDA through Type C and planned End-of-Phase 2 meetings to explore multiple regulatory pathways and potential expedited approval routes.
• Leveraging preclinical data from Department of Defense–sponsored studies to support the broader therapeutic potential of NVG-291-R in traumatic hearing loss and peripheral nerve injury.
• Advancing NVG-300 through preclinical test-of-concept studies in ischemic stroke and spinal cord injury.
• Using capital raised through equity programs and private placements to support clinical development, regulatory activities, and organizational growth.

Scientific and clinical positioning

NervGen positions NVG-291 as a first- and potential best-in-class therapeutic peptide targeting nervous system repair. The company’s disclosures highlight several aspects of its scientific and clinical positioning:

• NVG-291 is described as the first pharmacologic candidate to demonstrate statistically significant improvements in corticospinal connectivity with clinically meaningful functional gains in chronic cervical incomplete SCI.
• CONNECT SCI Study data include electrophysiological measures (such as motor evoked potentials) and functional assessments (including GRASSP scores and prehension measures), as well as patient-reported outcomes related to independence and quality of life.
• Neurophysiological findings, such as reductions in hyperactive reticulospinal signaling and improvements in corticospinal signaling, are presented as evidence of a biological basis for the observed clinical effects.
• Preclinical models of spinal cord injury, traumatic hearing loss, and peripheral nerve injury with NVG-291-R provide additional support for the candidate’s neuroreparative mechanisms and potential applicability across multiple nervous system injuries.

Through these elements, NervGen portrays itself as a company dedicated to advancing pharmacologic approaches that may challenge long-held assumptions about the limited capacity for nervous system repair after trauma, and to building a pipeline of candidates that apply similar principles of neurorepair across different neurologic conditions.